UKHSA extends vaccine contract, leveraging Liverpool manufacturing site
1 report, 1 independent
Updated Sep 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UK Health Security Agency extended its pandemic Advance Purchase Agreement with a vaccine developer for four years, through 2031. This agreement leverages the manufacturing site in Liverpool. The new vaccine, AUJEMFLU (aTIVc), is slated for introduction into the annual influenza vaccination program starting in the 2027/28 season.
From finanznachrichten.de
Why it matters
The contract extension reinforces the UK's capability for influenza pandemic and outbreak preparedness and response. The vaccine is noted as the first to combine three approaches to enhance protection for older and at-risk adults.
From finanznachrichten.de
Who's involved
- UK Health Security AgencyExtended the pandemic Advance Purchase Agreement and leveraged its manufacturing site.
- LiverpoolHosts the manufacturing facility that is central to the extended agreement.
Keep exploring
The entities involved
-
UK Health Security Agency
UK health agency
-
Liverpool
city in Merseyside, England, United Kingdom